Main Article Content


Drug interaction is a type of Drug-Related Problems (DRPs) that can
eventually increase morbidity and mortality rates. CKD patients have a
significant risk of developing polypharmacy due to comorbid diseases and
pharmacokinetics' alteration. The literature review was conducted by
exploring all of the articles related to the drug interaction using drug
interaction analysis program in CKD patients, which obtained from three
databases, namely Google Scholar, PubMed, and Science Direct, using
several keywords combination. Based on the comprehensive reviews
conducted, it is known that the most common effects of antihypertensive
drug interactions in CKD patients are decreasing effects of antihypertensive
drugs, hypotension, and hyperkalemia. Handling management used for the
emergence of potential drug interactions is based on the severity of the drug
interactions and complete knowledge of the patients' clinical condition. The
management of drug interaction by monitoring blood pressure, diuresis, and
potassium levels; Monitor the related effect symptoms; Monitor the fluid
and body weight; Monitor the kidney and heart function. On the condition
where the handling management of potential drug interactions is not carried
out, elevated morbidity and mortality rates are the risks of complications
arising from the drug interactions.


Drug Interactions Antihypertensive Chronic Kidney Disease

Article Details

Author Biographies

Ni Made Susilawati, Departemen Farmakologi dan Farmasi Klinik, Fakultas Farmasi, Universitas Padjadjaran, Sumedang.

Departemen Farmakologi dan Farmasi Klinik, Fakultas Farmasi, Universitas Padjadjaran, Sumedang, Jawa Barat, Indonesia.

Eli Halimah, Departemen Farmakologi dan Farmasi Klinik, Fakultas Farmasi, Universitas Padjadjaran, Sumedang,

Departemen Farmakologi dan Farmasi Klinik, Fakultas Farmasi, Universitas Padjadjaran, Sumedang, Jawa Barat, Indonesia

Siti Saidah, Instalasi Farmasi Rumah Sakit Umum Pusat Dr.Hasan Sadikin Bandung, Bandung.

Instalasi Farmasi Rumah Sakit Umum Pusat Dr.Hasan Sadikin Bandung, Bandung, Jawa Barat, Indonesia.

How to Cite
Ni Made Susilawati, Eli Halimah, & Siti Saidah. (2021). Review of Impact and Handling of Potential Antihypertensive Drug Interactions in Chronic Kidney Disease Patients: Review Dampak dan Penanganan Potensi Interaksi Obat Golongan Antihipertensi pada Pasien Penyakit Ginjal Kronis. Jurnal Farmasi Galenika (Galenika Journal of Pharmacy) (e-Journal), 7(1), 39-53.


  1. Adibe, M. O., Ewelum, P. C., & Amorha, K. C. (2017). Evaluation of drug-drug interactions among patients with chronic kidney disease in a South-Eastern Nigeria tertiary hospital: a retrospective study. Pan African Medical Journal, 28, 199.
  2. Armahizer, M. J., Kane-Gill, S. L., Smithburger, P. L., Anthes, A. M., & Seybert, A. L. (2013). Comparing Drug-Drug Interaction Severity Ratings between Bedside Clinicians and Proprietary Databases. ISRN Critical Care, 2013, 1–6.
  3. Becker, G. J., Wheeler, D. C., De Zeeuw, D., Fujita, T., Furth, S. L., Holdaas, H., … Zoccali, C. (2012). Kidney disease: Improving global outcomes (KDIGO) blood pressure work group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney International Supplements, 2(5), 337–414.
  4. Belaiche, S., Romanet, T., Allenet, B., Calop, J., & Zaoui, P. (2012). Identification of drug-related problems in ambulatory chronic kidney disease patients: a 6-month prospective study. J Nephrol, 25(5), 782–788.
  5. Bikbov, B., Purcell, C. A., Levey, A. S., Smith, M., Abdoli, A., Abebe, M., … Murray, C. J. L. (2020). Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet, 395(10225), 709–733.
  6. Busari, A. A., Oreagba, I. A., Oshikoya, K. A., Kayode, M. O., & Olayemi, S. O. (2019). High Risk of Drug–drug interactions among Hospitalized Patients with kidney Diseases at a Nigerian Teaching Hospital: A Call for Action. Nigerian Medical Journal: Journal of the Nigeria Medical Association, 60(6), 317.
  7. Chaliks, R. (2015). Factors Influence the Potential Drug Interaction Occurence among Hospitalized Patients with Cronic Kidney Disease at Labuang Baji Hospital Makassar. International Journal of Sciences: Basic and Applied Research, 24, 376–383.
  8. Cheung, A. K., Chang, T. I., Cushman, W. C., Furth, S. L., Ix, J. H., Pecoits-Filho, R., … Williamson, J. D. (2019). Blood pressure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 95(5), 1027–1036.
  9. Chinwendu, A. K., Joda, A. E., Oyetunde, O. O., & Udezi, W. A. (2017). Evaluation of drug-drug interactions among chronic kidney disease patients of nephrology unit in the University of Nigeria Teaching Hospital, Ituku-Ozalla, Enugu State. Journal of Basic and Clinical Pharmacy, 8, S049‑S053.
  10. Chisholm-Burns, M. A., Schwinghammer, T. L., Wells, B. G., Malone, P. M., Kolesar, J. M., & DiPiro, J. T. (Eds.). (2016). Pharmacotherapy Principles & Practice (Fourth). United States: McGraw-Hill Education.
  11. Cozzolino, M., Mangano, M., Stucchi, A., Ciceri, P., Conte, F., & Galassi, A. (2018). Cardiovascular disease in dialysis patients. Nephrology Dialysis Transplantation, 33(suppl_3), iii28–iii34.
  12. Fasipe, O. J., Akhideno, P. E., Nwaiwu, O., & Adelosoye, A. A. (2017). Assessment of prescribed medications and pattern of distribution for potential drug–drug interactions among chronic kidney disease patients attending the Nephrology Clinic of Lagos University Teaching Hospital in Sub-Saharan West Africa. Clinical Pharmacology: Advances and Applications, 9, 125.
  13. Ghanbari, Y., & Nagaraju, K. (2016). Identifying Drug-Drug Interaction Among Chronic Kidney Disease Patients in Tertiary Care Hospital. International Research Journal of Pharmacy, 7(7), 54–56.
  14. Hakim, L. (2016). Farmakokinetik Klinik (Pertama; I. Wardini, N. H. Riza, & A. Bimantara, eds.). Yogyakarta: Bursa Ilmu.
  15. Hassan, Y., Al-Ramahi, R., Aziz, N. A., & Ghazali, R. (2009). Drug use and dosing in chronic kidney disease. Annals Academy of Medicine Singapore, 38(12), 1095.
  16. Kheshti, R., Aalipour, M., & Namazi, S. (2016). A comparison of five common drug–drug interaction software programs regarding accuracy and comprehensiveness. Journal of Research in Pharmacy Practice, 5(4), 257.‑042X.192461
  17. Maas, R., & Böger, R. H. (2003). Antihypertensive therapy: special focus on drug interactions. Expert Opinion on Drug Safety, 2(6), 549–579.
  18. Marquito, A. B., Fernandes, N. M. da S., Colugnati, F. A. B., & Paula, R. B. de. (2014). Identifying potential drug interactions in chronic kidney disease patients. J. Bras. Nefrol., 36(1), 26–34.
  19. Okoro, R. N., & Farate, V. T. (2019). Evaluation of potential drug–drug interactions among patients with chronic kidney disease in northeastern Nigeria. African Journal of Nephrology, 22(1), 77–81.
  20. Olumuyiwa, J. F., Akinwumi, A. A., Ademola, O. A., Oluwole, B. A., & Ibiene, E. O. (2017). Prevalence and pattern of potential drug-drug interactions among chronic kidney disease patients in south-western Nigeria. Niger Postgrad Med J, 24(2), 88–92.
  21. Pugh, D., Gallacher, P. J., & Dhaun, N. (2019). Management of Hypertension in Chronic Kidney Disease. Drugs, 79(4), 365–379.
  22. Raddad, A. R., Rashed, A. O., Bsharat, A., Abu-Ghazaleh, D., Yasin, E., & Shehab, O. (2016). Evaluation of potential drug-drug interactions among Palestinian hemodialysis patients. BMC Nephrology, 17(1), 96.
  23. Rama, M., Viswanathan, G., Acharya, L. D., Attur, R. P., Reddy, P. N., & Raghavan, S. V. (2012). Assessment of Drug-Drug Interactions among Renal Failure Patients of Nephrology Ward in a South Indian Tertiary Care Hospital. Indian Journal of Pharmaceutical Sciences, 74(1), 63–68.
  24. Ricci, F., Fedorowski, A., Radico, F., Romanello, M., Tatasciore, A., Di Nicola, M., … De Caterina, R. (2015). Cardiovascular morbidity and mortality related to orthostatic hypotension: a meta-analysis of prospective observational studies. European Heart Journal, 36(25), 1609–1617.
  25. Rodieux, F., Wilbaux, M., van den Anker, J. N., & Pfister, M. (2015). Effect of kidney function on drug kinetics and dosing in neonates, infants, and children. Clinical Pharmacokinetics, 54(12), 1183–1204.
  26. Sabarirajan, S., & Shibina, K. (2020). Hypotension and homoeopathic management. International Journal of Homoeopathic Sciences, 4(2), 122–124.
  27. Saleem, A., Masood, I., & Khan, T. M. (2017). Clinical relevancy and determinants of potential drug-drug interactions in chronic kidney disease patients: results from a retrospective analysis. Integrated Pharmacy Research & Practice, 6, 71–77.
  28. Santos-Díaz, G., Pérez-Pico, A. M., Suárez-Santisteban, M. Á., García-Bernalt, V., Mayordomo, R., & Dorado, P. (2020). Prevalence of Potential Drug-Drug Interaction Risk among Chronic Kidney Disease Patients in a Spanish Hospital. Pharmaceutics, 12(8).
  29. Watanabe, R. (2020). Hyperkalemia in chronic kidney disease. Revista Da Associacao Medica Brasileira, 66(Suppl 1), 31–36.
  30. World Health Organization. (2020). World Health Statistics 2020: Monitoring health for the SDGs, Sustainable Development Goals (Vol. 21).